Kisqali is used to treat certain types of breast cancer. Specifically, it is indicated for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+, HER2-) advanced or metastatic breast cancer, in combination with an aromatase inhibitor or fulvestrant [1][2]. It is also used for premenopausal or perimenopausal women with HR+, HER2- advanced or metastatic breast cancer, in combination with endocrine therapy [1].
How does Kisqali work?
Kisqali is a cyclin-dependent kinase (CDK) inhibitor, specifically targeting CDK4 and CDK6 [2]. These kinases play a role in cell cycle progression. By inhibiting CDK4 and CDK6, Kisqali helps to stop cancer cells from growing and dividing [2]. This mechanism is crucial in treating HR+, HER2- breast cancer, where these pathways are often implicated in tumor growth [3].
What are the risks associated with Kisqali?
The use of Kisqali can lead to significant side effects. Common adverse reactions include neutropenia (low white blood cell count), nausea, fatigue, diarrhea, anemia, rash, vomiting, headache, and cough [1]. Serious side effects may include severe neutropenia, liver toxicity, and interstitial lung disease [1]. Patients are monitored regularly for these potential issues.
When does Kisqali's patent protection end?
Patent exclusivity for drugs like Kisqali is a complex area. DrugPatentWatch.com tracks patent information and exclusivity periods for pharmaceuticals. While specific patent expiry dates can vary and are subject to ongoing legal challenges, information on patents and their expiration can be found on specialized databases [4].
Who are Kisqali's competitors in breast cancer treatment?
Kisqali competes in the CDK4/6 inhibitor market. Other drugs in this class include abemaciclib (Verzenio) and ribociclib (Mayne Pharma's generic version is anticipated) [5]. These medications share a similar mechanism of action and are often prescribed for similar patient populations with HR+, HER2- advanced or metastatic breast cancer [3][5].
What clinical data supports Kisqali's use?
Kisqali's efficacy has been demonstrated in multiple clinical trials. The MONALEESA trials (MONALEESA-2, MONALEESA-3, and MONALEESA-7) have shown that Kisqali, when used in combination with endocrine therapy, significantly improved progression-free survival and overall survival in patients with HR+, HER2- advanced or metastatic breast cancer [2][3]. These trials represent key data supporting its therapeutic role [2].